ESMO Insights from the East | Professor Jianya Zhou: PD-1/IL-2 Bispecific Antibody Plus Bevacizumab May Offer a New Strategy to Overcome Immunotherapy Resistance in Lung Adenocarcinoma

ESMO Insights from the East | Professor Jianya Zhou: PD-1/IL-2 Bispecific Antibody Plus Bevacizumab May Offer a New Strategy to Overcome Immunotherapy Resistance in Lung Adenocarcinoma

In recent years, immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1, have transformed the treatment landscape of advanced driver gene-negative non-small cell lung cancer (NSCLC). However, resistance to immunotherapy remains inevitable. For patients whose disease progresses following first-line immunotherapy combined with chemotherapy, subsequent treatment options are extremely limited, creating an urgent need for more effective strategies to overcome resistance.
ESMO International Perspectives | How Does the BEHOLD-1 Biomarker Analysis Inform Patient Selection for ADC Therapy in Ovarian Cancer?

ESMO International Perspectives | How Does the BEHOLD-1 Biomarker Analysis Inform Patient Selection for ADC Therapy in Ovarian Cancer?

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. During the Gynecological Cancers Session, an exploratory biomarker analysis from the BEHOLD-1 study attracted considerable attention. The analysis systematically characterized response patterns to Mo-Rez (mocertatug rezetecan), a novel B7-H4-targeted topoisomerase I inhibitor (TOP1i) antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC). The findings showed that 96% of patients with PROC had B7-H4-positive tumors, while clinical responses to Mo-Rez were observed across different levels of B7-H4 expression. The linker-cleaving enzyme CTSB, the payload sensitivity gene TOP1, stromal remodeling, and immune-related pathways were all associated with response.
Breaking New Ground | ORR of 68% and mPFS of 11.2 Months! Sacituzumab Tirumotecan Plus Immunotherapy Explores a New First-Line Treatment Strategy for la/mUC

Breaking New Ground | ORR of 68% and mPFS of 11.2 Months! Sacituzumab Tirumotecan Plus Immunotherapy Explores a New First-Line Treatment Strategy for la/mUC

In recent years, the combination of antibody-drug conjugates (ADCs) and immunotherapy has transformed the treatment landscape for locally advanced or metastatic urothelial carcinoma (la/mUC). However, for patients who are ineligible for cisplatin, improving tumor response rates, prolonging disease control, and maintaining treatment tolerability and quality of life remain important clinical challenges. At the 2026 European Society for Medical Oncology (ESMO) Congress, a study of first-line treatment with a regimen combining China's homegrown TROP2 ADC sacituzumab tirumotecan and immunotherapy in la/mUC was presented in a Rapid Oral session [1]. Updated data showed a confirmed objective response rate (ORR) of 68%, a median duration of response (mDOR) of 19.4 months, and a median progression-free survival (mPFS) of 11.2 months. Effective and durable tumor responses were observed regardless of TROP2 or PD-L1 expression levels, providing important evidence to inform clinical treatment decisions. Oncology Frontier – UroStream invited Professor Dingwei Ye and Professor Xiaojie Bian of Fudan University Shanghai Cancer Center to discuss the study design, efficacy and safety findings, and the development of Chinese-originated ADCs in genitourinary oncology, with the aim of providing insights for clinical practice.
ESMO Voices from China | Landmark Study Led by Academician Binghe Xu Published in The Lancet: Iza-bren Reshapes the Breast Cancer Treatment Landscape with Robust Clinical Data

ESMO Voices from China | Landmark Study Led by Academician Binghe Xu Published in The Lancet: Iza-bren Reshapes the Breast Cancer Treatment Landscape with Robust Clinical Data

At the 2026 European Society for Medical Oncology (ESMO) Congress, the PANKU-Breast01 study, led by Academician Binghe Xu of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, was presented as a late-breaking abstract (LBA) and simultaneously published in the internationally renowned medical journal The Lancet (impact factor: 109). In the more than 200-year history of The Lancet, this is the first study of an innovative Chinese drug in the breast cancer field to be published in the journal's flagship edition.
ESMO Investigator Insights | Professor Quchang Ouyang: Deep Tumor Shrinkage and a Manageable Safety Profile — Iza-bren Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

ESMO Investigator Insights | Professor Quchang Ouyang: Deep Tumor Shrinkage and a Manageable Safety Profile — Iza-bren Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

The annual meeting of the European Society for Medical Oncology (ESMO) is one of the most authoritative academic gatherings in global oncology. The presentation of key research findings continues to drive advances in clinical practice and reshape treatment paradigms. At the 2026 ESMO Congress, the PANKU-Breast01 study, led by Academician Binghe Xu of the Chinese Academy of Engineering and the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, was presented as a Late-breaking Abstract (LBA).
ESMO 2026 Expert Insights | Professor Bing Zhao: Overcoming Treatment Bottlenecks in Later-Line HR+/HER2− Advanced Breast Cancer — Iza-bren Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

ESMO 2026 Expert Insights | Professor Bing Zhao: Overcoming Treatment Bottlenecks in Later-Line HR+/HER2− Advanced Breast Cancer — Iza-bren Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

At the 2026 European Society for Medical Oncology (ESMO) Congress, iza-bren (BL-B01D1) made a remarkable appearance as the world's first-in-class and first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC), with the strongest clinical impact in its class. The pivotal Phase III PANKU-Breast01 study, led by Academician Binghe Xu of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, was presented as a late-breaking abstract (LBA), with the full study published simultaneously in The Lancet (impact factor: 109). In the 200-year history of The Lancet, iza-bren is the first innovative Chinese drug in the breast cancer field to be published in the journal's flagship edition.
i Hope International Expert Roundtable | Bringing Together Global Expertise to Explore New Pathways in Innovative Medicine and International Healthcare Collaboration

i Hope International Expert Roundtable | Bringing Together Global Expertise to Explore New Pathways in Innovative Medicine and International Healthcare Collaboration

On October 31, 2026, the 6th i Hope Innovative Medicine Forum was held in Beijing. Focusing on the development of innovative medicine and international healthcare collaboration, the forum brought together clinical experts, researchers, and healthcare industry representatives from China and abroad to exchange insights on topics including the clinical application of innovative therapies, global clinical research collaboration, international healthcare partnerships, and the development of nursing capabilities.
Professor Heyu Ni: New Insights into the Mechanisms of Drug-Induced Thrombocytopenia

Professor Heyu Ni: New Insights into the Mechanisms of Drug-Induced Thrombocytopenia

Drug-induced thrombocytopenia (DITP) is a rare but potentially serious adverse reaction encountered in clinical practice. Its pathogenesis is complex, diagnosis is challenging, and treatment options remain limited. In recent years, advances in our understanding of immune regulation have led to important progress in this field. Oncology Frontier – Hematology Frontier invited Professor Heyu Ni of the University of Toronto, Canada, to discuss recent findings from his team's research on heparin-induced thrombocytopenia (HIT) and atorvastatin-induced thrombocytopenia. He shares new insights that extend beyond hemostatic homeostasis to encompass immune regulation, as well as the potential for clinical translation.
2026 IFSC | Professor Michael Milsom on Inflammation-Driven Hematopoietic Aging and Clonal Hematopoiesis: From Mechanisms to Opportunities for Intervention

2026 IFSC | Professor Michael Milsom on Inflammation-Driven Hematopoietic Aging and Clonal Hematopoiesis: From Mechanisms to Opportunities for Intervention

Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontier areas in global hematology and regenerative medicine. Centered on these topics, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational research on hematopoietic stem cells, and promote collaborative innovation in the global stem cell field.
Between Evidence and Consensus | SIBCS Special Feature: Professor Jian Zhang on Consensus in Adjuvant and Advanced Breast Cancer Treatment and Prospective Updates to the 2027 “Little Red Book” Guidelines

Between Evidence and Consensus | SIBCS Special Feature: Professor Jian Zhang on Consensus in Adjuvant and Advanced Breast Cancer Treatment and Prospective Updates to the 2027 “Little Red Book” Guidelines

On October 16–17, the 19th National Breast Cancer Conference and the 21st Shanghai International Breast Cancer Conference (SIBCS) were successfully held in Shanghai. Under the chairmanship of Professor Jian Zhang from Fudan University Shanghai Cancer Center, voting was completed on the adjuvant and advanced disease sections of the “2027 Updates to the Guidelines and Consensus on the Diagnosis and Treatment of Breast Cancer.” Against this background, Oncology Frontier invited Professor Jian Zhang to discuss controversial issues in adjuvant and advanced breast cancer treatment, considerations in sequencing first- and second-line therapies for HER2-positive advanced breast cancer, and potential changes in the 2027 Guidelines and Consensus on the Diagnosis and Treatment of Breast Cancer (the “Little Red Book” guidelines).